If it weren't for the Federal Trade Commission (FTC), PacBio would already be part of Illumina. Plans for a $1.2 billion merger that was first announced in November 2018 fell apart in January 2020 after the agency objected on anti-competitiveness grounds. For its trouble, Illumina paid PacBio a $98 million termination fee.